Description: A statewide section 1115 demonstration proposal has been developed to: provide a patient-focused system through managed care entities; build on the strengths of the current Maryland health care system; provide comprehensive, prevention-orientated systems of care; hold Managed Care Organizations (MCOs) accountable for high-quality care; and achieve better value and predictability for State expenditures.

Date Received: May 3, 1996.

State Contact: Mary Mussman, M.D., M.P.H., Acting Executive Director, Center for Health Program Development and Management, Social Sciences Building, Room 309A, 5401 Wilkens Avenue, Baltimore, MD 21228–5398, (410)455–6804.

Federal Project Officer: Gina Clemons, Health Care Financing Administration, Office of Research and Demonstrations, Office of State Health Reform Demonstrations, Mail Stop C3–18–26, 7500 Security Boulevard, Baltimore, MD 21244–1850.

Other pending proposals can be found in the Federal Register of January 23, 1996, 61 FR 1769.

3. Withdrawn Proposals

The following proposal was withdrawn June 4, 1996:

Demonstration Title/State: The Granite State Partnership for Access and Affordability in Health Care—New Hampshire.

B. Other Section 1115 Demonstration Proposals

1. New Proposals

No new proposals were received during the month of June.

2. Approved Proposals

The following proposal was approved during the month of June:

Demonstration Title/State: Medicaid Family Planning Services for Women of Childbearing Age—Arkansas.

Description: This State demonstration will provide Medicaid covered family planning services for all women of childbearing age with incomes at or below 133 percent of the Federal Poverty Level.

Date Received: September 13, 1995 (October 2, 1995 date listed in 61 FR 1771 was not correct).

Date Approved: June 18, 1996.

State Contact: Thomas Dalton, Director, Arkansas Department of Human Services, P.O. Box 1437, Little Rock, Arkansas 72203–1437, (501) 682–8650.

Federal Project Officer: Rosemarie Hakim, Health Care Financing Administration, Office of Research and Demonstrations, Mail Stop C3–24–07, 7500 Security Boulevard, Baltimore, MD 21244–1850.

3. Pending and Withdrawn Proposals

We did not disapprove any Other Section 1115 Demonstration Proposals during June nor were any proposals withdrawn during that month. Pending proposals for the month of November 1995 published in the Federal Register on January 23, 1996, 61 FR 1769, and for the months of February and March 1996 published in the Federal Register on May 14, 1996, 61 FR 24318 remain unchanged with the exception of the approved proposal as shown above.

III. Requests for Copies of a Proposal

Requests for copies of a specific Medicaid proposal should be made to the State contact listed for the specific proposal. If further help or information is needed, inquiries should be directed to HCFA at the address above.

(Catalog of Federal Domestic Assistance Program, No. 93.779; Health Financing Research, Demonstrations, and Experiments.)

Dated: July 24, 1996.

Barbara Cooper,

Acting Director, Office of Research and Demonstrations.

[FR Doc. 96–20918 Filed 8–15–96; 8:45 am]

BILLING CODE 4120–01–P

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meetings

Pursuant to Public Law 92–463, notice is hereby given of the meetings of the following Heart, Lung, and Blood Special Emphasis Panels.

These meetings will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contract Persons listed below in advance of the meetings.

Name of Panel: New Therapies for Thalassemia.

Dates of Meeting: September 16, 1996.

Time of Meeting: 10:00 a.m.

Place of Meeting: National Institutes of Health, Rockledge Building II, 6701 Rockledge Drive, Room 10158, Bethesda, Maryland 20892.

Agenda: To develop strategies for implementing clinically-related recommendations from the NHLBI Report on ''Cooley's Anemia: Progress in Biology and Medicine—1995'' as a future initiative.

Contact Person: Alan S. Levine, NHLBI/DBDR, Two Rockledge Center, 6701 Rockledge Drive, Rm. 10158, MSC 7950, Bethesda, Maryland 20892, Bethesda, Maryland, 20892, (301) 435–0050.

Name of Panel: Bone Marrow Transportation in Sickle Cell Anemia.

Dates of Meeting: September 24, 1996.

Time of Meeting: 10:00 a.m.

Place of Meeting: Natcher Building, LL-Room J, 45 Center Drive, Bethesda, Maryland 20892.

Agenda: To review current progress and identify future research initiatives in the use of bone marrow transplantation for the treatment of Sickle Cell Anemia.

Contact Person: Helena Mishoe, NHLBI/DBDR, Two Rockledge Center, 6701 Rockledge Drive, Rm. 10156, MSC 7950, Bethesda, Maryland 20892, Bethesda, Maryland 20892, (301) 435–0050.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: August 9, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–20941 Filed 8–15–96; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the following Heart, Lung, and Blood Special Emphasis Panel.

The meeting will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contact Person listed below in advance of the meeting.

Name of Panel: Cardiac Arrhythmias in Children.

Dates of Meeting: August 29, 1996.

Time of Meeting: 8:30 a.m.

Place of Meeting: Natcher Building 45, Conference Room B, 45 Center Drive, Bethesda, Maryland 20892.

Agenda: To evaluate the nature and severity of arryhythmias occurring in children on psychotropic drugs, and those that occur after cardiac surgery and recommend research priorities for future initiatives.

Contact Person: Thomas J. Doubt, NHLBI/DHVD, Two Rockledge Center, 6701 Rockledge Drive, Room 9044, MSC 7940, Bethesda, Maryland 20892, (301) 435–0540.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: August 9, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–20942 Filed 8–15–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Institute of Mental Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: August 13, 1996.

Time: 2:15 p.m.

Place: Parklawn Building, Room 9C–18, 5600 Fishers Lane, Rockville, MD 20857.

Contact Person: W. Gregory Zimmerman, Parklawn Building, Room 9C–18, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443–1340.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: August 16, 1996.

Time: 4 p.m.

Place: Parklawn Building, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857.

Contact Person: Phyllis D. Artis, Parklawn Building, Room 9C–26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443–6470.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281, 93.282)

Dated: August 12, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–20940 Filed 8–13–96; 1:24 pm]

BILLING CODE 4140–01–M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESS: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Allan Kiang, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7735 ext 270; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Immunization With Synthetic Peptides Generate Cytotoxic T Cell Responses Against the EWS/FL1 1 Ewing's Sarcoma Fusion Protein and the PAX–3/FKHR Alveolar Rhabdomysarcoma Fusion Protein

TJ Goletz, LJ Helman, JA Berzofsky (NCI), Filed 14 Sept 95, Serial No. 08/528,129

This invention provides novel methods of producing vaccines and therapeutics to viral infections or cancer(s). This method utilizes irradiated, peptide-pulsed antigen presenting cells (APCs) which are coated with synthetic or recombinant peptides. These APCs can be used to induce a tumor specific cytotoxic T lymphocyte (CTL) response. This broadly applicable method uses safe, non-toxic synthetic or recombinant peptides and does not utilize harmful adjuvants or live viral vectors. Peptides derived from viral or bacterial antigens or mutant oncogene or tumor suppressor gene products may be applied towards this method. For example, using this method, a synthetic peptide which corresponds to the site of the mutation in the tumor suppressor gene product p53 can be used to induce a CTL response which kills tumor cells endogenously expressing the mutant p53 gene. (portfolio: Cancer—Therapeutics, biological response modifiers; Cancer—Therapeutics, vaccines)

O-Malonlytyrosyl Compounds, O-Malonllytyrosyl Compound-Containing Peptides, and Uses Thereof

TR Burke, B Ye, M Akamatsu, X Yan, HK Kole, PR Roller (NCI), Filed 31 Mar 95, Serial No. 08/414,520

Phosphotyrosyl residues in signalling proteins, which appear to act as molecular switches in phosphotyrosyl-dependent cellular signal transduction pathways, are potential targets for therapeutic agents. The phosphotyrosol-dependent signal transduction pathway is composed of three elements: the protein kinases which add phosphates to tyrosine residues, the protein phosphatases which remove the phosphate, and the interaction of other signaling proteins with proteins containing phosphotyrosyl residues. This invention describes a phosphotyrosyl mimetic 0-malonyltryosine (OMT) which uses a malonate moiety in place of phosphate that can be derivatized and thus potentially made permeable to cell membranes. Peptides containing OMT residues are therefore potential therapeutic agents for disease states with altered cellular signaling including cancer. (portfolio: Cancer—Therapeutics, conventional chemotherapy, antimetabolites)

Assay for Sensitivity of Tumors to DNA-Platinating Chemotherapy

E Reed, M Dadholkar, F Bostick-Burton (NCI), Filed 07 Mar 95, Serial No. 08/399,617

The invention provides a method for determining the sensitivity of a tumor tissue to treatment with platinum-based chemotherapy. The method is based on detecting high levels of the mRNA for ERCC1 which includes exon VIII or concurrent expression of ERCC1 and XPAC mRNAs in fresh tumor tissues. Studies show that this method clearly distinguishes between platinum-sensitive and platinum-resistant tumors (J. Clin. Invest. 94:703–708, 1994). (portfolio Cancer—Research Reagents, DNA based)

Confirmationally Constrained Diacylglycerol Analogues

VE Marquez, J Lee, R Sharma, S Wang, GWA Milne, MC Nicklaus, PM Blumberg, NE Lewin (NCI), Filed 13 Jan 95, Serial No. 08/372,602

Diacylglycerol (DAG) is a member of the second messenger system in cell signal transduction. DAG is released from membrane phospholipids in response to the binding of a variety of agonists. Once released, DAG binds to the regulatory domain of protein kinase C (PK–C) and in doing so aids in the activation of the kinase. PK–C, when activated, is capable of phosphorlyating a variety of other proteins involved in cellular processes including growth, differentiation, inflammation, nerve function, tumor promotion, and ocogenic expression. Given the global action of PK–C, molecules that can activate or inactivate this enzyme would be very useful. The claims of this